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An increasing number of people, students in particular, seek substances that improve their cognitive functioning. The 
most popular group of pharmacological cognitive enhancers (PCEs) are stimulants. Available studies suggest a small 
beneficial effect of methylphenidate and amphetamine on memory, executive functions, and processing speed. However 
small, this effect can make the difference between success and failure. In recent years, research has focused on the 
additional beneficial effect on the emotional state, increased motivation, and placebo-induced cognitive enhancement. 
This paper briefly reviews the latest and most important research on the relationship between popular stimulants and 
cognitive enhancement. One cannot understand this relationship without understanding the Yerkes-Dodson law, which 
explains the relationship between the degree of arousal and performance. It suggests that the effect of stimulants is a 
dose-dependent continuum. This law has repeatedly been confirmed by studies in which an optimal level of psychoactivation 
for cognitive enhancement was obtained with low stimulant doses, whereas exceeding the effective dose resulted in 
cognitive deficits, psychomotor agitation, and addiction. A separate section has been devoted to modafinil, an increasingly 
popular stimulant that differs from the rest in neurochemical profile and behavioural effects.
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An increasing number of students and employees use 
substances considered to be cognitive performance 
enhancers to improve their academic and/or professional 
results. The most common group of substances used for 
these reasons are stimulants such as amphetamine. In many 
countries these substances are legal and registered for the 
treatment of various disorders. However, even when 
clinically indicated, they raise much doubt and apprehension 
because of their addictive potential. This review summarises 
the latest and most important information on the 
epidemiology, efficacy, and mechanisms of action of 
stimulants used for cognitive enhancement. It further 
explores the relationship between stimulant dose and 
cognitive performance based on the Yerkes-Dodson law.
The concept of cognitive enhancement refers to the 
multifaceted improvement of human cognitive abilities in 
a healthy population. There are various methods to achieve 
it, including pharmacological, biotechnological, and those 
involving information technology (1–3). In ancient 
civilizations, pro-cognitive substances such as hallucinogens 
were supposed to facilitate contact with deities (4). Today, 
pharmacological cognitive enhancement is one of the most 
commonly discussed topics in the neuroscience community 
(4, 5). Some scientists consider the use of pharmacological 
substances away of fulfilling the eternal human desire for 
self-improvement (6).
LITERATURE SEARCH
This review is based on MEDLINE database search 
using English key terms related to pharmacological 
cognitive enhancement and the use of the most common 
stimulants for this purpose, namely amphetamine, 
methylphenidate, and modafinil. We excluded other 
stimulants, non-stimulant cognitive enhancers (e.g. 
racetams and vinpocetine) or drugs used by patients with 
Alzheimer’s disease or Parkinson’s disease with dementia 
(e.g. acetylcholinesterase inhibitors like donepezil and 
rivastigmine or NMDA receptor agonists like memantine) 
to improve cognitive functions impaired by their 
neurodegenerative disorders.
We used the following query: cognitive enhanc*[Title/
Abstract] AND (amphetamine [Title/Abstract] OR 
methylphenidate*[Title/Abstract] OR modafinil [Title/
Abstract]) and set the publication date range from 1 January 
2000 to 2 May 2019. The resulting 228 hits, in our opinion, 
did not reflect all the important publications on the subject 
matter. For this reason, we repeated the search with each 
of the above-mentioned key words alone. The resulting hits 
added the latest publications, some of which explained the 
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about cases of prescription extortion by parents are easy to 
encounter in the press. These cases fall into two categories: 
parents want their child to perform as well as their peers at 
school “my child must be on methylphenidate, because all 
the others are taking it!” (20) or a drug prescribed for a 
child is actually used as a stimulant by the parent (21, 22).
In turn, 4.4 % of US adults aged 18 to 44 years suffer 
from ADHD (23), but misuse of stimulants has been 
reported in adults with and without ADHD (24, 25).
In a 2008 systematic review Wilens et al. (24) 
established that 16–29 % of students prescribed with 
stimulants were at least once asked to give, sell, or trade 
their medication. Similarly, Poulin (26) reported that 26 % 
of the surveyed students prescribed with stimulants admitted 
to have given or sold some of their medication to their peers 
in the past month. As this diversion often occurs between 
peers at school or college – an environment where students 
seek to achieve success – the issue may seem less serious 
than drug abuse found in more marginalised environments 
(18). In any case, as many as 10 % of youth aged 12–25 
years who have abused stimulants in the past year may meet 
the criteria for substance dependence (27).
A drug that is becoming increasingly available as a 
“lifestyle drug” improving performance in healthy 
individuals is modafinil. In addition to its indicated use to 
treat narcolepsy-related sleepiness, it is legally distributed 
among healthy American, British, French, and Indian 
soldiers, as it helps them remain awake after a sleepless 
night, which is particularly useful in military conditions. In 
the US it has replaced amphetamine, previously used for 
this purpose (28, 29). However, it is also often sold illegally 
online (30).
Whether we like it or not, stimulants are used legally 
and illegally, which raises the issue of broadening legal use 
of stimulants. Proponents of legalisation point out that 
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pharmacological mechanisms of these substances. This 
review includes 90 key publications, the majority of which 
are review articles (including current systematic reviews 
and meta-analyses) and original research articles, but due 
to the popularity of the subject, we also included chapters 
from books, internet publications, and press reports.
In order to make the content of the review more 
understandable, we also included basic information about 
the Yerkes-Dodson law, based mainly on the original results 
of the authors’ experiment.
DEFINITION AND EPIDEMIOLOGY OF 
PCE
Pharmacological cognitive enhancement (PCE) is 
defined as an increase in cognitive functions – memory, 
attention, creativity, and intelligence (understood as a 
problem-solving skill) in particular – in healthy individuals 
with the help of prescription drugs not medically indicated 
for this purpose (3, 4). This is well illustrated by population 
studies involving college students – a group predisposed to 
use PCEs and thus the most thoroughly studied in terms of 
PCE use (7–11).
The most common pharmacological cognitive enhancers 
(PCEs) are stimulants used in the treatment of attention 
deficit hyperactivity disorder (ADHD), and/or narcolepsy. 
and include amphetamine salts, methylphenidate, and 
modafinil (7, 12–15).
Methylphenidate and amphetamine salts (or simply 
amphetamine) are most commonly used in the USA for 
ADHD (16). In 2016, 5.1 % of all US children between 2 
and 17 years was taking some form of ADHD medication 
(17), whereby researchers estimate that as many as 30 % 
(11.4 million) of prescriptions intended for children with 
ADHD are used outside their indication (18, 19). Articles 
Figure 1 Stimulant dose- and route-dependent cognitive performance [based on a review by Wood et al. (49)]
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regarding the misuse and diversion of stimulants prescribed 
for ADHD. The rate of non-medical use in the past year 
ranged from 5 % to 9 % in grade-school and high-school 
children and from 5 % to 35 % in college students. These 
35 % were, in fact, reported by Low and Gendaszek (37) 
among the 150 participating students of undergraduate 
psychology classes, 80 % of whom misused ADHD 
prescription drugs to enhance their performance at school. 
These findings are comparable to those reported by Webb 
et al. (36) for a similar sample of medical students. In the 
Barrett et al. study (38), which was also included in the 
systematic review by Wilens et al. (24), 70 % of respondents 
misused stimulants recreationally, whereas 30 % did it in 
order to study more effectively. Teter et al. (39) conducted 
an internet survey among 4580 college students. It turned 
out that the most commonly reported motives for stimulant 
misuse were to improve concentration (65.2 %), facilitate 
studying (59.8 %), and increase alertness (47.5 %). Other 
motives included getting high (31.0 %) and experimenting 
(29.9 %). Another web-based study (40) among 2,877 
German university students from randomly selected 
disciplines reported high cognitive anxiety about the 
consequences of failing, low intrinsic motivation, low 
internalisation of social norms against cognitive enhancers, 
and positive past experiences as motives for misuse.
SCIENTIFIC EVIDENCE OF EFFICIENT 
COGNITIVE ENHANCEMENT BY 
STIMULANTS
Substances used in the treatment of ADHD at clinically 
relevant doses improve cognitive functioning associated 
with frontostriatal pathways in ADHD patients and healthy 
individuals (16). In 2014, Bagot and Kaminer (18) published 
a systematic review of data collected from 14 randomised, 
double-blind, placebo controlled trials on the effectiveness 
of stimulants (methylphenidate, amphetamine, and 
modafinil) in enhancing cognitive function in healthy youth 
(12–25 years) without ADHD diagnosis. Methylphenidate 
appeared to significantly improve performance in novel 
tasks and attention-based tasks (P≤0.05), while reducing 
planning latency in more complex tasks (P≤0.05). The 
review also showed that amphetamine significantly 
improved memory consolidation (P≤0.05), which led to 
improved recall, whereas modafinil, whose mechanism of 
action differs from typical stimulants (see below) appeared 
to improve reaction time (P≤0.04), logical reasoning 
(P≤0.05), and problem-solving.
In 2015, Ilieva et al. (41) published a meta-analysis of 
48 double-blind, placebo-controlled trials with a total of 
1,409 participants – all healthy young and middle-aged 
individuals – showing that the effects of amphetamine and 
methylphenidate on cognitive functions crucial for 
academic and occupational functioning were rather small 
but significant for inhibitory control (inhibiting dominant 
professions such as a doctors, surgeons, or judges could 
benefit from a reasonable use of stimulants (see the Yerkes-
Dodson law below) and so could the society (8, 29).
THE USE OF PCEs AMONG STUDENTS OF 
MEDICINE AND OTHER PROFESSIONS
Nowadays, healthy students at universities around the 
world often acquire prescription stimulants not to get 
intoxicated (“get high”) – as can be the case with 
amphetamine or methylphenidate (known in street slang as 
the poor man’s cocaine) (31) – but to improve their 
academic performance (18, 29). This phenomenon is 
considered a growing global trend (18). Medical students 
constitute a special group, because of the amount of material 
they are required to absorb, and in many countries academic 
performance is a decisive factor in the choice of internship 
and specialisation. The duration of their studies is longer 
than in other fields, which makes it difficult to earn a living 
on the side. This puts them at risk of using legal and illegal 
substances in order to improve their academic performance 
and cope with stress.
One would expect that medical students use stimulants 
more often than other students, as suggested by some recent 
reports (8, 32), but this may be misleading, as they compare 
their results with a decade older study by McCabe et al. 
(33) on a large sample of students of various professions, 
who may not have been as well acquainted with stimulants 
as they are now. In the meanwhile, stimulants have become 
more popular and better studied. This raises a need to 
compare the current frequency of stimulant use by students 
of medical universities and other universities.
In 2011, Emanuel et al. (34) conducted an internet 
survey that included over 1,000 medical students in 
Chicago. Eleven percent of respondents admitted using 
non-prescription stimulants during studies. A 2010 study 
with nearly 400 US medical students (35) reported a similar 
percentage (10.1 %) of misuse. Webb et al. (36) reported a 
higher percentage (15 %) but in a relatively small sample 
of 144 medical students. Nine percent of respondents, 
however, had a confirmed diagnosis of ADHD, which is 
almost twice as high as in the general adult population of 
adults (23). Eighty-three percent of the respondents using 
stimulants reported that they did it to enhance their cognitive 
performance or to stay awake longer while on clinical 
duties.
The 2004 McCabe et al. study (33) reported that 6.9 % 
of nearly eleven thousand college students at various US 
universities admitted having misused stimulants at least 
once in their lifetime. Using multivariate regression 
analysis, they found that non-medical use was the most 
common among white male college students who were 
members of fraternities and sororities, and had lower grade 
point averages. In 2008, Wilens et al. (24) published a 
systematic review of 21 studies with 213,104 participants 
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behaviour for the sake of achieving the goal) (Hedges’ 
g=0.20), working memory (g=0.13), and short-term 
episodic memory tested up to 30 minutes after learning 
(g=0.20). A moderate effect size (g=0.45) was found only 
in delayed episodic memory, tested one hour to one week 
after learning. As the authors conclude, these results suggest 
that memory consolidation is affected by stimulants to a 
greater degree than memory encoding or retrieval. This 
conclusion confirms earlier reports (42–44).
Ilieva et al. (41) also speculated that amphetamine and 
modafinil might improve other learning-adjacent domains 
of cognition such as processing speed. This speculation was 
later confirmed in a systematic meta-analysis by Marracini 
et al. (45) based on double-blind placebo-controlled trials, 
which showed that prescription stimulants positively 
influenced processing speed in healthy adults (overall mean 
size effect of g=0.282). Planning time, planning accuracy, 
cognitive perseveration, or advantageous decision-making 
were neither improved nor impaired, although these 
outcomes were investigated only in a small number of 
studies.
Taking into consideration their previous work, Ilieva et 
al. (41, 46) do not exclude the possibility that the benefits 
of PCEs in healthy individuals are partly owed to elevated 
mood and motivation and not only to their effects on 
cognitive function. In fact, they suggest that while 
individuals with depression or undiagnosed ADHD may 
benefit from stimulants, those with anxiety or bipolar 
disorder may suffer adverse effects due to excessive arousal. 
They admit, however, that only future, properly designed 
studies should be able to confirm this hypothesis. Theirs 
and other studies show that stimulants might alter emotional 
approach to a task, so that individuals who ingested a 
stimulant experience more satisfaction and change their 
perception of the task from unattractive to attractive (46, 
47). Interestingly, a placebo-controlled study from 2017 
(48) suggested that stimulant-induced cognitive 
enhancement might in fact largely depend on individual 
expectations rather than purely pharmacologic action 
(placebo-induced cognitive enhancement).
PCE-INDUCED COGNITIVE 
ENHANCEMENT OR DECLINE IS DOSE-
DEPENDENT
The use of stimulants, even in the case of ADHD 
treatment, raises certain concerns in the society. This is 
understandable, because the term stimulants is also 
associated with the negative consequences of 
psychoactivation such as addiction, excessive psychomotor 
agitation, and aggressive behaviour (16, 29). However, 
when it comes to ADHD treatment or cognitive enhancement, 
such concerns have not yet been scientifically founded.
In a 2014 review Wood et al. (49) focused on animal 
studies, including their own, examining the relationship 
between stimulant dose and psychoactivation, including an 
increase or decrease in cognitive function. At low, clinically 
relevant doses of stimulants administered orally they 
observed cognitive enhancement accompanied with a slight, 
beneficial increase in arousal and motor activation (see also 
the Yerkes-Dodson law below). Higher doses and/or rapid 
routes of administration (e.g. injections) resulted in adverse 
hyperlocomotion and euphoria (the latter being closely 
related to addiction). Still higher psychoactivation impaired 
cognitive function. Further dose increase was associated 
with the symptoms of overdose, such as agitation, 
confusion, and psychosis, and eventually circulatory failure 
and death. This, in terms of stimulants, is called a continuum 
of psychoactivation (49). According to Spencer et al. (16), 
low stimulant doses selectively increase the concentration 
of catecholamines in the pre-frontal cortex, which, in turn, 
act on norepinephrine α2 and dopamine D1 receptors and 
enhance cognitive function. They also point to a stark 
contrast between the regionally selective action of low 
stimulant doses and the non-selective effects of higher 
doses. Research and imaging studies have shown the pre-
frontal cortex is critically involved in memory tasks (50–
52), guiding behaviour during divided attention (53), and 
planning (54).
THE RELATIONSHIP BETWEEN AROUSAL 
AND PERFORMANCE
The Yerkes-Dodson law
One of the oldest proposals regarding the relationship 
between the degree of arousal and the level of task-oriented 
functioning (e.g. learning speed) is based on the research 
of Robert Yerkes and John Dodson. In 1908, the two 
published the results of a study that examined the influence 
of strength of electrical stimuli on the speed at which mice 
learned how to distinguish fields with different intensity of 
illumination. With a simpler task, which was to avoid fields 
with clearly stronger light intensity, the learning time 
decreased linearly with the increase of the stimulus. With 
a more difficult task (to distinguish two fields with similar 
light intensity), the learning curve assumed the shape of an 
inverted “U”, as learning was the quickest with moderate 
stimulus, achieving the optimal level of arousal (Figure 2) 
(55).
Further research by Yerkes (56) and Dodson (57) 
confirmed these findings. In the years that followed, other 
authors (58–60) replicated these experiments using more 
modern research methods for measurement and statistical 
analysis. In 1957, Broadhurst (59) reported a noticeable 
decrease in rat performance when faced with a difficult task 
at high level of body stress. With easy tasks, in contrast, 
the highest stress level had the best influence on performance. 
In 2010, Salehi et al. (60) confirmed the inverted U-shape 
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function of memory and stress intensity in rats performing 
a hippocampus-dependent learning task.
Yerkes’s and Dodson’s experiments lay the foundation 
for the Yerkes-Dodson law, which says that a high level of 
arousal can improve performance with easy tasks or worsen 
it with difficult tasks. According to Diamond et al. (61), 
learning how to perform easy task is a simple learning 
condition that involves focused attention to an isolated cue 
with minimal cognitive (decision-making) demands. More 
complex or challenging learning conditions are associated 
with performing a difficult task demanding divided attention 
and/or strongly involving working memory.
Some researchers explain low tolerance of arousal in 
difficult tasks with the reticular formation triggering 
mechanisms that prevent the awareness of all incoming 
information or simplifying it. Without this regulation, the 
body would be unable to cope with the complexity of reality 
reaching awareness. This would lead to disorganisation of 
its response (62).
According to more recent studies summarised by 
Lafreniere in an introduction to the reversal theory in 
psychology (63), the impact of arousal on functioning may 
also depend on the meta-motivational status of the 
individual towards the surrounding reality. Taking into 
account the Yerkes-Dodson law, in the telic state (also 
known as “serious” state), where subjects are focused on 
achieving a specific goal, they should avoid excessive 
stimulation, as it would generate negative emotions (e.g. 
anxiety) and decrease performance. In the paratelic (or 
playful) state, in turn, when the focus is on the activity 
instead of the goal, additional stimulation may increase 
efficacy.
In addition to situational conditions, personality factors 
are also important. It has been proven that people differ in 
their persistent attitude to functioning in the telic or paratelic 
state, which largely determines the differences in the 
efficiency of their functioning in certain states of emotional 
arousal (63, 64). Salehi et al. (60) not only confirmed the 
Yerkes-Dodson law but also evidenced individual 
differences in rat performance at either high or low stress 
conditions. They suggest that personality types may differ 
in their cognitive performance when exposed to stress, but 
this hypothesis needs to be tested in human studies.
In terms of stimulants, these concerns are justified, 
because healthy individuals may not have a purely cognitive 
benefit from PCEs. Instead, it may at least partly result from 
motivation, higher energy levels, and influence on affective 
states (41, 46).
Nowadays, the conclusions drawn from Yerkes-Dodson 
studies (55–58) are widely applied in many areas, including 
athletic training, computer gaming, and workplace design 
(58).
MODAFINIL: NOT A TYPICAL 
STIMULANT
Amphetamine  and  methy lphen ida te  b lock 
norepinephrine and dopamine reuptake, which, in turn, 
strongly increases their extracellular levels. Amphetamine 
also stimulates dopamine efflux through an action believed 
to involve the entry of the drug into dopamine terminals 
and a reversal in the operation of the dopamine reuptake 
transporter. Amphetamine can also stimulate norepinephrine 
efflux and block serotonin reuptake, though this only occurs 
at quite high and clinically inappropriate doses (16). In 
contrast to amphetamine, methylphenidate neither inhibits 
serotonin reuptake nor stimulates norepinephrine or 
dopamine efflux (65). In line with the continuum of 
psychoactivation, at low doses amphetamine and 
methylphenidate preferentially target the pre-frontal cortex 
(16, 66), which is responsible for cognitive enhancement, 
whereas at higher doses their action is not preferential and 
affects subcortical areas as well, resulting in motor 
activation and arousal (16, 67, 68).
Modafinil, in turn, affects several neurotransmitter 
pathways, including dopamine and norepinephrine (69), 
5-HT (70), GABA (71), glutamate (72) and histamine, 
Figure 2 A subset of data from Yerkes and Dodson (55) (left) presented in the form of a graph by Diamond et al. (61) (right) showing 
the relationship between arousal and performance of simple and complex tasks. The smaller the number of trials to criterion, the faster 
the mice learned. The optimal level of mice arousal (electric shock stimulation) was recorded only when the difficult task was performed
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which some studies reported to be orexin-mediate (73), 
though its mechanism of action has yet to be discovered. 
Because of its wake-promoting properties, it has been 
regarded as a stimulant, but several animal and human 
studies suggest that its mechanism of action differs from 
that of classic stimulants. Its primary therapeutic mechanism 
appears to be dopamine reuptake via dopamine transporter, 
some of its stimulant profile may be owed to non-
dopaminergic mechanisms (74).
In 2010, Repantis et al. (3) published a meta-analysis 
of 31 single- or double-blind randomised or quasi-
randomised controlled clinical trials, including cross-over 
clinical trials, which compared modafinil with placebo in 
healthy individuals. Single-dose modafinil had moderate 
enhancing effects on attention in non-sleep-deprived, well-
rested individuals compared to a placebo, but no statistical 
difference was found for memory, mood, or motivation. In 
sleep-deprived individuals single-dose modafinil 
significantly enhanced wakefulness, executive functions, 
and memory without effects on mood. Repeated intake of 
modafinil during sustained sleep deprivation over several 
days maintained higher wakefulness than placebo, and this 
effect lasted for up to four days. However, attention and 
executive functions were not sustained with repeated doses. 
Repeated administration of modafinil to well-rested 
individuals was reported by only two studies, whose 
combined samples were not sufficient for statistical analysis.
A few years later, Battleday and Brem (2) published a 
systematic review of 24 randomised, double-blind, placebo-
controlled prospective studies, all performed on healthy, 
non-sleep-deprived subjects. In simple tasks, modafinil 
improved executive function, variably enhanced attention, 
learning, and memory, but did not affect creativity and 
motor excitability. In complex tasks it enhanced attention, 
executive function, learning, and memory. Negative 
cognitive effects were reported occasionally and never 
consistently for any of the functions. Positive effects on 
mood were minimal, but Repantis et al. (75) commented in 
a letter to the editor that Battleday et. al failed to provide a 
definition of mood.
As for sleep-deprived healthy patients, Wesensten et al. 
(76) examined their alertness and performance after taking 
modafinil in therapeutic doses (200 or 400 mg) compared 
to caffeine use (600 mg). Wakefulness and performance 
improved in respect to placebo controls and corresponded 
to results achieved with caffeine. This was later confirmed 
by another study of the same authors (77) in healthy, sleep-
deprived patients who received 400 mg of modafinil or 
600 mg of caffeine. Both substances improved psychomotor 
vigilance speed and objectively measured alertness 
compared to a placebo. A similar enhancement was also 
observed for some aspects of the executive function (e.g. 
improved learning on the Wisconsin Card Sorting Test and 
better performance on the Biber Cognitive Estimation Test).
Modafinil also appears to improve decision-making, as 
evidenced by Franke et al. (78), who had their subjects play 
chess against a computer program. These improvements, 
however, were evident only when the subjects were not 
under the pressure of time.
Modafinil has a low abuse potential (79) and at 
therapeutic doses does not produce euphoria in either 
substance abusers (80) or healthy subjects (81). A recent 
study (82) has showed that doses low enough not to cause 
hyperarousal (200 mg and 400 mg) were enough to achieve 
domain-specific attention enhancement in healthy, non-
sleep-deprived participants. However, rare cases of 
modafinil dependence do exist (83, 84). While still 
enhancing cognitive function in healthy people, a single 
dose of 600 mg increased neural activation in the brain 
regions linked to fear processing (85). Due to its unique 
psychostimulatory profile, modafinil could be useful in the 
treatment of cocaine (86) and methamphetamine (87) 
addiction. Furthermore, it might improve cognition in 
methamphetamine-dependent individuals, as suggested by 
Ghahremani et al. (88).
CONCLUSION
Latest research indicates that stimulant-assisted 
performance enhancement is not owed to the beneficial 
effects on cognitive functioning alone but also to improved 
motivation and mood. In fact, some of the pro-cognitive 
effects may be owed to placebo.
What is important to note is that low and clinically 
indicated doses administered orally are not associated with 
adverse reactions typical of this group of drugs. Instead, 
psychoactivation is moderate, which favours cognitive 
enhancement. Psychoactivation is desirable for maximising 
our cognitive abilities, and we have learned so far that its 
optimal level depends on the difficulty of the task 
performed, personality, and current metamotivational state. 
This review, we hope, has successfully pointed out the 
beneficial effects of optimal psychoactivation per se. It does 
not necessarily need to stem from stimulant use, and we 
believe that better understanding of psychoactivation can 
improve work, education, and many other areas of life.
Another important finding we would like to point out 
is that stimulation may help with the performance of simple 
tasks (with a small number of cues requiring focus) but is 
rather counterproductive in complex and challenging tasks 
that engage more working memory. According to the 
reversal theory, it is important to realise whether satisfaction 
derives from performing a task (additional stimulation is 
beneficial) or from completing it (additional stimulation 
should be limited).
Stimulant use might be associated with reduced need 
to sleep. While such an effect could seem desirable if we 
were to assume that sleeping is a waste of time, even a 
short-term sleep disruption leads not only to depression and 
anxiety but also cause cognitive deficits (89, 90). Long-term 
sleep disruption, in turn, increases the risk of civilisation 
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diseases and intensifies symptoms of many gastrointestinal 
conditions (89,90). With all that in mind, uninformed use 
of stimulants could create a vicious circle (stimulants cause 
sleep disruption which produces cognitive deficits, which 
inclines us to use more stimulants). In contrast, practical 
use of knowledge on psychoactivation can improve our 
quality of life.
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U potrazi za optimalnom psihoaktivacijom – stimulansi kao pojačivači kognitivne funkcije
Sve više ljudi, napose studenata, traži tvari kojima će poboljšati svoju kognitivnu funkciju. Najpopularniji među 
farmakološkim pojačivačima kognitivne funkcije jesu stimulansi. Rezultati dostupnih istraživanja pokazuju blago, povoljno 
djelovanje metilfenidata i amfetamina na pamćenje, izvršne funkcije i brzinu obrade (procesiranja). Premda je poboljšanje 
blago, ono u studenata može značiti razliku između uspjeha i neuspjeha. Posljednjih se je godina istraživanje usmjerilo 
na dodatne povoljne učinke stimulansa na emocionalno stanje, povećanu motivaciju, pa i na kognitivna poboljšanja 
povezana s placebom. U ovom se radu daje kratki pregled najnovijih i najvažnijih istraživanja odnosa između popularnih 
stimulansa i poboljšanja kognitivne funkcije. Taj se odnos ne može razumjeti bez poznavanja Yerkes-Dodsonova zakona, 
koji objašnjava odnos između razine uzbuđenosti i izvedbe (performanse) te govori o tome da stimulansi djeluju u 
kontinuumu koji je ovisan o dozi. Zakon je opetovano potvrđivan istraživanjima u kojima je optimalna razina psihoaktivacije 
za poboljšanje kognitivne funkcije postignuta niskim dozama stimulansa, a previsoke razine dovodile su do pada kognitivnih 
deficita, psihomotorne agitacije i ovisnosti. Dio je teksta posvećen modafinilu, sve popularnijem stimulansu koji se svojim 
neurokemijskim svojstvima i djelovanjem na ponašanje razlikuje od ostalih.
KLJUČNE RIJEČI: amfetamin, metilfenidat, modafinil, stimulansi središnjega živčanoga sustava
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